ALERT: Your health is top priority. We’re committed to providing reliable COVID-19 resources to keep you informed and safe.


Effexor (venlafaxine) was the first antidepressant in the class of drugs known as serotonin-norepinephrine reuptake inhibitors (SNRIs). It is available in an extended-release formula to treat depression, and anxiety and panic disorders. It works by regulating levels of serotonin and norepinephrine in the brain.

The U.S. Food and Drug Administration approved Effexor in 1993 to treat major depressive disorder in adults. An extended-release version called Effexor XR won FDA approval in 1997. Both formulas contain the same active ingredient, venlafaxine.

Wyeth Pharmaceuticals Inc. manufactured both the original and extended-release versions until Pfizer acquired the company in 2009. Today, Pfizer only markets the extended-release version, which is also approved to treat generalized anxiety disorder, social anxiety disorder and panic disorder.

The FDA approved the first generic version in 2010. Generic versions of the original formula are still available.

Venlafaxine is a serotonin-norepinephrine reuptake inhibitor, or SNRI. It helps block the reabsorption of both serotonin and norepinephrine, two chemicals in the brain that transmit nerve signals.

Close Up of the Re-absorption of Serotonin & Norepinephrine
Effexor blocks the reabsorption of serotonin and norepinephrine.

Scientists believe maintaining proper levels of serotonin in the brain prevents depression and anxiety, and they also think boosting norepinephrine reduces neuropathic pain.

Research suggests venlafaxine may be more effective and cause fewer side effects than selective serotonin reuptake inhibitors, a slightly older class of antidepressants that focuses solely on serotonin and includes Prozac, Paxil and Zoloft.

Taking Effexor Safely

Pfizer discontinued the original version of Effexor in part because it required two or three doses per day while the extended-release version allows for a single daily dose for most patients.

Suggested dosages for venlafaxine are significantly higher compared to many SSRI antidepressants. The capsules come in 37.5 mg, 75 mg and 150 mg strengths.

Effexor 37.5 mg pill
Effexor XR 37.5mg
Effexor 75 mg pill
Effexor XR 75mg
Effexor 150 mg pill
Effexor XR 150mg

The medication guide instructs patients to take the drug with food at the same time each day. The medicine can make you sleepy, or make it harder for you to think clearly or react quickly. So, until you know how you will respond to the medication, it’s important to avoid driving, operating heavy machinery or doing other dangerous activities.


Mixing venlafaxine with therapies that also affect serotonin levels, such as other antidepressants, linezolid, lithium, tramadol and St. John’s wort, can cause a condition called serotonin syndrome that raises blood pressure, heart rate and body temperature.

Let your doctor know of all prescription and over-the-counter medications and supplements you have taken or plan to take, including aspirin, migraine medications, amphetamines, antipsychotics and blood thinners.

Don’t start using Effexor XR within two weeks of taking a medication known as an MAOI, and don’t take an MAOI within a week of stopping venlafaxine.

Taking the medication with blood thinners or nonsteroidal anti-inflammatory drugs like Advil and Motrin may increase the risk of bleeding side effects. The medication guide also advises against drinking alcohol while taking the drug.

Recommended Dosages

Dosage and administration can be complicated and is detailed in a chart on the package insert. The recommended starting dose for major depressive disorder, generalized anxiety disorder and social phobia is 75 mg per day, but doctors may instruct some patients to start with 37.5 mg to allow their body to adjust to the medication. The recommended starting dose for patients with panic disorder is 35 mg per day.

Depending on need and how a patient tolerates venlafaxine, a doctor may increase the dose to 150 mg per day and then up to 225 mg per day. This is accomplished using 75 mg increments at intervals of no less than four days.

The maximum recommended dose for moderately depressed patients is 225 mg per day, but patients with severe depression may respond better to higher doses.

One study referenced in the drug’s label found severely depressed patients responded to an average dose of 350 mg per day. But it’s unknown whether such patients need that high of a dose, and the label notes experience with venlafaxine doses higher than 225 mg per day is “very limited.”

Adjusting the Dose for Kidney or Liver Problems

The dose a doctor prescribes is unique to each patient. Do not change your dosage without consulting your doctor or pharmacist.

The medication guide recommends doctors reduce the total daily dose by 50 percent in patients with mild to moderate liver failure, also known as hepatic impairment. It may be necessary to reduce the dose even more than 50 percent in some patients.

A reduced dose is also recommended for patients with kidney problems. The medication guide says doctors should reduce the dose by 25 percent for patients with a history of kidney failure and by 50 percent for patients undergoing hemodialysis.

Stopping Treatment

It’s unclear how long patients with depression, generalized anxiety disorder, social phobia or panic disorders should continue to take Effexor. During clinical studies for depression, the drug was effective up to 52 weeks without having to adjust the dose. The drug’s label advises doctors to periodically reassess the need for the medication.

Never stop taking venlafaxine without a doctor’s direction. Abruptly stopping the drug or decreasing the dose too quickly can cause serious withdrawal symptoms, including extreme fatigue, confusion, dizziness, headaches and shock-like electrical sensations.

Side Effects and Warnings

Among the most unwanted effects of venlafaxine are those related to sexual dysfunction such as lack of interest in sex, difficulty becoming aroused and the inability to achieve orgasm. Other reactions commonly reported in clinical trials include nausea, dry mouth, constipation and sweating.

The more serious Effexor side effects, however, involve pregnant or nursing women, children, teens and young adults. Venlafaxine is not approved for use in pediatric patients, and the medication guide warns pregnant or nursing women not to take the drug without discussing the risks with their doctor.

Newborns whose mothers took the drug in the third trimester of pregnancy may experience serious problems right after delivery, including seizures and problems feeding and breathing. And the drug may pass through breast milk and harm a nursing baby.

Still, the drug’s strongest warning is a black box warning for suicidal thoughts and behaviors in patients under the age of 25.

Off-Label Uses

Although the FDA approved Effexor XR to treat four illnesses, doctors may prescribe the drug for other conditions. These unapproved treatments are called off-label uses.

A 2017 Canadian study published in The British Medical Journal looked at adults who visited certain physicians between January 2003 and September 2015 and were prescribed an antidepressant through an electronic prescribing system.

Researchers found nearly a third of the 106,850 antidepressant prescriptions written for 20,920 patients were for off-label uses. And researchers determined only about 16 percent of off-label uses were backed up by medical research.

The researchers found SNRIs such as venlafaxine and SSRIs were the less likely to be prescribed for off-label uses. But Effexor has been used to treat conditions for which it has never been approved.

Diabetic Neuropathy

A 2010 review published by American Family Physician called SNRI antidepressants like venlafaxine “a promising category of antidepressants for treatment of diabetic peripheral neuropathic pain.” It cited a 2004 study in the journal Pain that found high doses of venlafaxine significantly reduced pain in diabetic neuropathy patients.

It also pointed to a 2007 Cochrane review that looked at three small studies on treating diabetic neuropathy with the drug. It found venlafaxine’s effectiveness at reducing pain was similar to that of tricyclic antidepressants such as amoxapine or desipramine.

“[SNRIs] are a promising category of antidepressants for treatment of diabetic peripheral neuropathic pain.”

Source: American Family Physician, Jul. 15, 2010]

However, a 2017 Cochrane review analyzed six trials involving neuropathic pain in general. It questioned the limits of the studies and cited considerable risk of bias in them.

“We found little compelling evidence to support the use of venlafaxine in neuropathic pain,” the researchers wrote in their conclusion.


Effexor is also prescribed off-label to treat debilitating migraines. In April 2012, a neurologist from the Jefferson Headache Center at Thomas Jefferson University in Philadelphia presented new migraine treatment guidelines at the annual meeting of the American Academy of Neurology that formalized the drug’s role. The guidelines were published in the journal Neurology.

Hot Flashes

Venlafaxine has also been used for the off-label treatment of hot flashes associated with menopause. A study published in the Journal of the American Medical Association in 2006 found women who took the drug reported 60 percent fewer hot flashes. The study found the drug worked best at high doses, which meant an increased risk of side effects. Women should carefully weigh those risks against the benefits.

effexor pill
Effexor XR Facts
  1. Uses Major depressive disorder, generalized anxiety disorder, social anxiety disorder, panic disorder
  2. Side Effects Suicidal thoughts and behavior, serotonin syndrome, changes in blood pressure, abnormal bleeding, eye problems, withdrawal symptoms, birth defects, miscarriage
  3. Manufacturers Wyeth Pharmaceuticals Inc. (acquired by Pfizer Inc. in 2009)
  4. Active Ingredient Venlafaxine
  5. Administration Route Oral
  6. Available Strength 37.5, 50, 75, 150 mg
  7. Dosage Form Tablet, capsule
  8. Drug Class Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
  9. Is Available Generically True
  10. Is Proprietary True
  11. RxCUI 39786

Please seek the advice of a medical professional before making health care decisions.

Related Pages
Terry Turner
Written By Terry Turner Writer

Terry Turner has been writing articles and producing news broadcasts for more than 25 years. He covers FDA policy, proton pump inhibitors, and medical devices such as hernia mesh, IVC filters, and hip and knee implants. An Emmy-winning journalist, he has reported on health and medical policy issues before Congress, the FDA and other federal agencies. Some of his qualifications include:

  • American Medical Writers Association (AMWA) and The Alliance of Professional Health Advocates member
  • Centers for Disease Control and Prevention Health Literacy certificates
  • Original works published or cited in Washington Examiner, MedPage Today and The New York Times
  • Appeared as an expert panelist on hernia mesh lawsuits on the BBC
Edited By
Emily Miller
Emily Miller Managing Editor
Medically Reviewed By
Dr. Joseph Palermo
Dr. Joseph Palermo Osteopathic Medicine

20 Cited Research Articles writers follow rigorous sourcing guidelines and cite only trustworthy sources of information, including peer-reviewed journals, court records, academic organizations, highly regarded nonprofit organizations, government reports and interviews with qualified experts. Review our editorial policy to learn more about our process for producing accurate, current and balanced content.

  1. Harrison, C. et al. (2004, June 1). Tolerability of High-Dose Venlafaxine in Depressed Patients. Journal of Psychopharmacology. Retrieved from
  2. Kaplan, K. (2012, April 23). Experts issue new guidelines for preventing migraines with drugs. Los Angeles Times. Retrieved from
  3. Nakhai-Pour, H.R., Broy, P., and Berard, A. (2010, July 13). Use of Antidepressants During Pregnancy and the Risk of Spontaneous Abortion. Canadian Medical Association Journal. Retrieved from
  4. National Institute of Mental Health. (2016, October). Mental Health Medications. Retrieved from
  5. National Library of Health (2013). Actos (pioglitazone). Daily Med. Retrieved from
  6. National Library of Health (2016, May 31). Label: Effexor (venlafaxine tablet). Daily Med. Retrieved from
  7. National Library of Medicine. (n.d.). Effexor 150. Creative Commons. Retrieved from
  8. National Library of Medicine. (n.d.). Effexor 27.5. Creative Commons. Retrieved from
  9. National Library of Medicine. (n.d.). Effexor 75. Creative Commons. Retrieved from
  10. Ozyalcin, S. et al (2005, February 10). The Efficacy and Safety of Venlafaxine in the Prophylaxis of Migraine. Retrieved from
  11. Parker-Pope, T. (2007, October 9). Antidepressants Emerge as Coolant for Hot Flashes. Retrieved from
  12. Pfizer. (2018, December). Effexor XR Label. Retrieved from
  13. Polen, K.N. et al. (2012, December 26). Association Between Reported Venlafaxine Use in Early Pregnancy and Birth Defects, National Birth Defects Prevention Study, 1997-2007. Centers for Disease Control and Prevention. Retrieved from
  14. Rowbotham, M.C., et al. (2004, August). Venlafaxine Extended Release in the Treatment of Painful Diabetic Neuropathy: A Double-Blind, Placebo-Controlled Study. Pain. Retrieved from
  15. Saarto, T. and Wiffen P.J. (2007, October 17). Antidepressants for Neuropathic Pain. Cochrane Database of Systematic Reviews. Retrieved from
  16. Silberstein, S.D. et al. (2012, April 24). Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults. Retrieved from
  17. U.S. Food and Drug Administration. (2006, July). Information for Healthcare Professionals: Selective Serotonin Reuptake Inhibitors (SSRIs), Selective Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), 5-Hydroxytryptamine Receptor Agonists (Triptans). Retrieved from
  18. U.S. Food and Drug Administration. (2007, May 2) FDA Drug Safety Communication: Antidepressant Use in Children, Adolescents, and Adults. Retrieved from
  19. U.S. Securities and Exchange Commission. (2008, February 29). FORM 10-K PFIZER INC. Retrieved from
  20. Wong, J. et al. (2017, February 21). Off-Label Indications for Antidepressants in Primary Care: Descriptive Study of Prescriptions from an Indication Based Electronic Prescribing System. The BMJ. Retrieved from
View All Sources
Who Am I Calling?

Calling this number connects you with a Drugwatch representative. We will direct you to one of our trusted legal partners for a free case review.

Drugwatch's sponsors support the organization's mission to keep people safe from dangerous drugs and medical devices. For more information, visit our sponsors page.

(888) 645-1617